TB-HIV Co-infections

TB-HIV co-infection accelerates disease progression and increases mortality risk. Simultaneous treatment of TB and HIV presents challenges, including drug interactions and cumulative toxicities, necessitating careful management.

TB-HIV co-infection accelerates disease progression, increasing the risk of active TB development in HIV-positive individuals. TB worsens HIV outcomes, while HIV weakens TB immunity, leading to more severe and disseminated TB disease. Management challenges include drug interactions, overlapping symptoms, and immune reconstitution inflammatory syndrome (IRIS). Simultaneous treatment of both diseases is essential, often requiring complex drug regimens and close monitoring. Integration of TB and HIV services improves patient outcomes, emphasizing early diagnosis, treatment initiation, and adherence support. Prevention strategies include HIV testing, antiretroviral therapy, TB screening, and infection control measures to reduce transmission in high-burden settings.

    Related Conference of TB-HIV Co-infections

    April 23-24, 2026

    14th Annual Congress on Pulmonary and Critical Care

    Paris, France
    April 27-28, 2026

    2nd World Congress on Pathology and Laboratory Medicine

    Paris, Aland Islands
    June 11-12, 2026

    5th World Summit on COPD

    Rome, Italy

    TB-HIV Co-infections Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in